Full-spectrum Medical Cannabis for Treatment of Spasticity in Patients With Severe Forms of Cerebral Palsy
Key facts
- Who runs it
- University Medical Centre Ljubljana
- Where
- Slovenia2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 55 people enrolled
- Started
- 15 Oct 2020
- Ended
- 29 Feb 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Lab tests
- ECG
- Cannabinoid Levels
- Full-spectrum Medical Canabis Product (HemPhar)
- Placebo
- Spasticity level according to modified Ashworth scale (Bohannon)
- Gross Motor Function Measure
- Borg rating of perceived exertion scale
- Edmonton symptom assessment system
- Record updated
- 22 May 2024
Who can take part
- Age
- 5 years to 25 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- With confirmed diagnosis of cerebral palsy (CP) and classified according to the Gross Motor Function Classification System (GMFCS) as level IV or V
- With spastic unilateral or spastic bilateral type of CP
- Those children/young adults whose parents/caregivers were informed about the aims of the study and have signed the Informed consent form
Who cannot take part
- Other proven diseases/conditions with the prevalence of spastic type of muscle tone (e.g. neurodegenerative, metabolic, etc.), and children with liver disease
- History of psychiatric illness/condition in the family
- Other forms of CP (dyskinetic, ataxic)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The proposed study is a double-blind, placebo-controlled, cross over study on 60 children aged 5 to 25 years with severe spasticity related to cerebral palsy (CP), level IV and V with full-spectrum medical cannabis product of CBD/THC ratio 10:1.
The 2 groups in the trial
- Active Substance: Full-spectrum Medical Canabis Product (HemPhar)Existing treatment, for comparison
For research purposes the investigators will use a preparation in the form of drops, containing full-spectrum medical cannabis extract (HemPhar) with THC:CBD ratio 1:10, and other cannabinoids as well, provided by Pharmahemp, GMP-certified medical cannabis producer.
Treatment: Lab tests, ECG, Cannabinoid Levels, Full-spectrum Medical Canabis Product (HemPhar), Spasticity level according to modified Ashworth scale (Bohannon), Gross Motor Function Measure, Borg rating of perceived exertion scale, and Edmonton symptom assessment system
- PlaceboPlacebo, for comparison
For research purposes the investigators will use a placebo in the form of drops, containing oil only, provided by Pharmahemp, GMP-certified medical cannabis producer.
Treatment: Lab tests, ECG, Placebo, Spasticity level according to modified Ashworth scale (Bohannon), Gross Motor Function Measure, Borg rating of perceived exertion scale, and Edmonton symptom assessment system
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Full-spectrum Medical Canabis Product (HemPhar) With a CBD:THC Ratio of 10:1 for Treatment of Spasticity in Children and Young Adults With Severe Forms of Cerebral Palsy
- Record updated
- 22 May 2024